Gyre THERAPEUTICS, Inc. (GYRE) intrinsic value & 10-year financials
Gyre THERAPEUTICS, Inc. (GYRE) has a Graham intrinsic value of $0.66 per share. At $6.08 on Oct 17, 2026, the stock trades 821% above that value. Over the last 10 fiscal years revenue grew 87.9% a year to $116.6M, with an average return on invested capital of 11.0%.
- Graham intrinsic value
- $0.66
- Share price (Oct 17, 2026)
- $6.08
- Price vs Graham value
- 821% above
- Market cap
- $627.3M
- Revenue (FY2025)
- $116.6M
- Revenue growth (10-yr CAGR)
- 87.9%
- ROIC (10-yr avg)
- 11.0%
- Free cash flow (FY2025)
- -$180.0K
GYRE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $116.6M | $9.9M | $0.02 | -$180.0K | 9.9% | 12.7% |
| FY2024 | $105.8M | $17.9M | $0.05 | -$6.0M | 15.3% | 766.0% |
| FY2023 | $113.5M | -$85.5M | -$1.41 | $17.4M | -59.3% | 145.6% |
| FY2022 | $102.3M | -$8.2M | -$0.13 | -$38.1M | -8.4% | 37.4% |
| FY2021 | $7.3M | -$87.9M | -$1.44 | -$84.6M | -1197.8% | -401.2% |
| FY2020 | $20.9M | -$56.2M | — | — | -273.9% | -111.4% |
| FY2019 | — | -$55.2M | — | -$43.7M | — | -101.6% |
| FY2018 | $6.0K | -$30.1M | — | -$28.9M | -563700.0% | -39.9% |
| FY2017 | $1.0M | -$21.6M | — | -$20.0M | -2143.6% | -92.1% |
| FY2016 | $399.0K | -$16.9M | — | -$18.9M | -5117.3% | -105.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
GYRE THERAPEUTICS, INC. is a consistent compounder, expanding top-line revenue at 87.9% annually over the past decade.
GYRE THERAPEUTICS, INC. has historically struggled to out-earn its cost of capital, averaging just -2.0% ROIC.
GYRE THERAPEUTICS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, GYRE THERAPEUTICS, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.66 per share.